Immunovant IMVT
NASDAQ IMVT
$37.04 +1.33 (+3.72%)
At close: Nov 11, 2026 · 4:00 PM EST

Immunovant (IMVT) Other Accumulated Expenses (2019 - 2026)

Updated

Immunovant's Other Accumulated Expenses came in at $175,000 for fiscal Q4 2026 (quarter ended Mar 31, 2026), down 35.9% from $273,000 a year earlier.

Analysis

Immunovant (IMVT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends

Going back to fiscal Q4 2023, Immunovant's Other Accumulated Expenses data covers 4 quarters.

  • Other Accumulated Expenses carries a three-year compound annual growth rate of -20.6% (FY2023 to FY2026).
  • Going back by fiscal year, Other Accumulated Expenses was $273,000 in FY2025, $15,000 in FY2024 (-95.7%) and $350,000 in FY2023.
  • The fiscal Q4 2026 figure represents the lowest quarterly Other Accumulated Expenses since fiscal Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Immunovant 7.38 Bn 3.97 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 175,000.00
Mar 31, 2025 273,000.00
Mar 31, 2024 15,000.00
Mar 31, 2023 350,000.00
Mar 31, 2022 171,000.00
Sep 30, 2020 134,000.00
Jun 30, 2020 336,000.00
Mar 31, 2020 3.19 Mn
Dec 31, 2019 3.13 Mn
Mar 31, 2019 58,000.00
API Access

Immunovant Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IMVT&period=max&api_key=YOUR_API_KEY